Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Wednesday

Annovis Bio (NYSE:ANVS) is anticipated to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Annovis Bio to announce earnings of ($0.30) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.

Annovis Bio (NYSE:ANVS) last released its earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.05. On average, analysts expect Annovis Bio to post ($1.32) EPS for the current fiscal year and ($0.54) EPS for the next fiscal year.

Annovis Bio Price Performance

Shares of NYSE:ANVS opened at $1.09 on Wednesday. Annovis Bio has a 1 year low of $0.93 and a 1 year high of $5.50. The firm has a market capitalization of $46.73 million, a PE ratio of -0.61 and a beta of 1.36. The business’s 50 day moving average price is $1.23 and its 200-day moving average price is $1.91.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wall Street Zen lowered Annovis Bio from a “sell” rating to a “strong sell” rating in a report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annovis Bio in a report on Friday, October 2nd. Canaccord Genuity Group reiterated a “buy” rating on shares of Annovis Bio in a research report on Tuesday, August 18th. Zacks Research raised shares of Annovis Bio to a “hold” rating in a research note on Thursday, July 9th. Finally, Roth Capital lowered their price target on shares of Annovis Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Annovis Bio Company Profile

Annovis Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on therapies designed to address mechanisms associated with neurodegeneration rather than treating only individual symptoms.

Annovis Bio’s lead product candidate is buntanetap, formerly known as ANVS401. Buntanetap is an orally administered small molecule being investigated for its potential to reduce the production of multiple neurotoxic proteins linked to neurodegenerative disorders.